Reply to Correspondence on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Dhanasekaran R, Suzuki H, Lemaitre L, Kubota N, Hoshida Y
. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making. Hepatology. 2023; 81(3):1038-1057.
PMC: 10713867.
DOI: 10.1097/HEP.0000000000000513.
View
2.
Ock C, Hwang J, Keam B, Kim S, Shim J, Jang H
. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 2017; 8(1):1050.
PMC: 5648801.
DOI: 10.1038/s41467-017-01018-0.
View
3.
Lee Y, Fujiwara N, Yang J, Hoshida Y
. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology. 2022; 78(1):319-362.
PMC: 9995677.
DOI: 10.1002/hep.32779.
View
4.
Yim S, Lee S, Baek S, Sohn B, Jeong Y, Kang S
. Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial. Clin Mol Hepatol. 2024; 30(4):807-823.
PMC: 11540371.
DOI: 10.3350/cmh.2024.0333.
View
5.
Zeng Q, Klein C, Caruso S, Maille P, Allende D, Minguez B
. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study. Lancet Oncol. 2023; 24(12):1411-1422.
DOI: 10.1016/S1470-2045(23)00468-0.
View